Founder of Peptidings.com. Former big tech product manager. Independent peptide researcher focused on translating clinical evidence into accessible science.
First Head-to-Head Comparison of Semaglutide, Tirzepatide, and Retatrutide Shows Tirzepatide Leading—in Mice A preclinical study compared all three GLP-1 analogs
The First Large Trial Testing a GLP-1 Drug for Long COVID Just Finished Enrolling—in Under Two Months Scripps Research’s LoCITT-T
A landmark 503A peptide review is now officially underway. The FDA announced on April 16, 2026, that its Pharmacy Compounding
GHK-Cu is now the fastest-growing peptide in consumer search—and the gap between interest and evidence has never been wider. Somewhere
The FDA peptide reclassification process took its most significant step forward on Tuesday. On Tuesday, the FDA announced it will
Retatrutide just delivered Phase 3 results that redefine what’s possible in pharmaceutical weight loss—and raised new questions about tolerability. Eli
A landmark study on GLP-1 side effects just surfaced symptoms that clinical trials may be missing. A team at the
Peptides Are Having a Moment April 8, 2026 In the first week of April 2026, something happened that doesn’t normally
While Eli Lilly consolidates its lead in the obesity therapeutics market, a second wave of companies is advancing candidates that
A physician writing in STAT News on April 3 described a patient who refuses to take a statin — a drug